175 related articles for article (PubMed ID: 21490594)
1. Pharmacological mechanism-based drug safety assessment and prediction.
Abernethy DR; Woodcock J; Lesko LJ
Clin Pharmacol Ther; 2011 Jun; 89(6):793-7. PubMed ID: 21490594
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
3. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
Kweder SL
Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
[No Abstract] [Full Text] [Related]
4. Improving the reporting of adverse drug reactions in the hospital setting.
Pushkin R; Frassetto L; Tsourounis C; Segal ES; Kim S
Postgrad Med; 2010 Nov; 122(6):154-64. PubMed ID: 21084792
[TBL] [Abstract][Full Text] [Related]
5. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
6. The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety.
Woo J; Wolfgang S; Batista H
Clin Pharmacol Ther; 2008 Mar; 83(3):494-7. PubMed ID: 18253142
[TBL] [Abstract][Full Text] [Related]
7. Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation.
Ball D; Blanchard J; Jacobson-Kram D; McClellan RO; McGovern T; Norwood DL; Vogel W; Wolff R; Nagao L
Toxicol Sci; 2007 Jun; 97(2):226-36. PubMed ID: 17369604
[TBL] [Abstract][Full Text] [Related]
8. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence.
Matthews EJ; Frid AA
Regul Toxicol Pharmacol; 2010 Apr; 56(3):247-75. PubMed ID: 19932726
[TBL] [Abstract][Full Text] [Related]
9. Assessing the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project--six sites, United States, January 1-June 15, 2004.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Apr; 54(15):380-3. PubMed ID: 15843786
[TBL] [Abstract][Full Text] [Related]
10. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
11. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
12. US drug shortages are set to reach record high in 2011, report says.
Tanne JH
BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406
[No Abstract] [Full Text] [Related]
13. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
14. The state of dietary supplement adverse event reporting in the United States.
Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
16. Food and Drug Administration's Safe Use Initiative collaborating to reduce preventable harm from medications.
U S Food And Drug Administration
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):76-93. PubMed ID: 20345207
[No Abstract] [Full Text] [Related]
17. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
18. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
19. A regulatory perspective on issues and approaches in characterizing human metabolites.
Davis-Bruno KL; Atrakchi A
Chem Res Toxicol; 2006 Dec; 19(12):1561-3. PubMed ID: 17173368
[TBL] [Abstract][Full Text] [Related]
20. The FDA drug safety surveillance program: adverse event reporting trends.
Weiss-Smith S; Deshpande G; Chung S; Gogolak V
Arch Intern Med; 2011 Mar; 171(6):591-3. PubMed ID: 21444854
[No Abstract] [Full Text] [Related]
[Next] [New Search]
